Global Pneumococcal Vaccines Market key Insights Based on Product Type, End-use and Regional Demand Till 2028 || Key Players - Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc., and Merck & Co. Inc.

A fresh report has been added to the wide database of Market Research Report Search Engine (MRRSE). The research study is titled “Global Pneumococcal Vaccines Market key Insights Based on Product Type, End-use and Regional Demand Till 2028” which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview.

Pneumococcal disease is an infection caused by Streptococcus pneumonia. Pneumococcal infection can result in pneumonia, bacteremic pneumonia, bacteremia, meningitis, bloodstream infection, and middle ear infection. There are two main types of pneumococcal diseases, namely non-invasive and invasive pneumococcal diseases. Invasive pneumococcal diseases, such as bacteremia (sepsis), meningitis and bacteremic pneumonia, tend to be more serious compared to non-invasive. Serotypes 1, 4, 5, 7F, 8, 12F, 14, 18C, and 19A are more likely to cause invasive pneumococcal diseases.

To Get Sample Copy of Report, Click here @ https://www.mrrse.com/sample/17206

According to the World Health Organization, pneumonia accounted for 16% deaths of children aged under 5 year in 2015. Pneumococcal vaccines are used against streptococcus pneumonia. There are 2 types of pneumococcal vaccines available—conjugate vaccines and polysaccharide vaccines. The WHO has recommended pneumococcal conjugate vaccines in the routine immunization for children. In this report, the pneumococcal vaccines market is further categorized into product type and distribution channel. The report provides market size and forecast for pneumococcal vaccines against Streptococcus pneumonia, inclusive of both types of vaccines. The report analyses the demand for pneumococcal vaccines form pharmacies, public health agencies, community clinics, and other distribution channels.

In terms of revenue, the global pneumococcal vaccines market is projected to expand at 9.1% CAGR over the forecast period of 2018–2028. The pneumococcal vaccines market is expected to be valued at US$ 18,456.5 Mn by 2028 end. The addition of pneumococcal vaccine national immunization programs and development of new pneumococcal vaccines are expected to boost the growth of the global pneumococcal vaccines market over the forecast period. According to the World Health Organization, pneumococcal vaccines were added to the national immunization programs of 138 countries till 2017.

Browse Complete Report with TOC @ https://www.mrrse.com/global-pneumococcal-vaccines-market

The global demand for pneumococcal vaccines is growing as a result of increasing initiatives by government and private organizations to provide vaccination in developing countries. Public-private partnerships to provide low-cost pneumococcal vaccines in middle-income countries is also expected to propel the growth of the pneumococcal vaccines market. Pneumococcal vaccines are introduced in more than 57 Gavi-supported countries under the advance market commitment. Development of pneumococcal vaccines for all age groups is expected to create favorable growth opportunities for the pneumococcal vaccines market. Likewise, increasing awareness among parents regarding vaccination, catch up champignons to reduce IPD risk and partnerships & funding for development of new vaccines are expected to boost the growth of the global pneumococcal vaccines market. However, low immunization coverage for new pneumococcal vaccines, slow introduction of vaccines in middle-income countries, low awareness among older population regarding pneumococcal vaccination are some of the factors expected to hamper the growth of the pneumococcal vaccines market.

Geographically, the global pneumococcal vaccines market is segmented into seven major regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific (Asia-Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America was the dominant regional market for pneumococcal vaccines in 2017 and is expected to expand at a high CAGR of 10.2% over the forecast period of 2018–2028.  The Asia Pacific is expected to contribute significant revenue share in the global pneumococcal vaccine market due to increasing government funding and the addition of pneumococcal vaccines in national immunization programs in the region.

Examples of some of the key players identified in the global pneumococcal vaccines market are Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc., and Merck & Co., Inc., among others. Manufacturers are focusing on research and development activities to develop multivalent pneumococcal vaccines. Pfizer Inc. and GlaxoSmithKline Plc. have collaborated with Gavi vaccine alliance to supply their pneumococcal vaccines in Gavi-supported countries. Through this collaboration, both the companies have increased their presence in the market and contribute to the immunization program.

Enquire about this Report @ https://www.mrrse.com/enquiry/17206

About Market Research Reports Search Engine (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: https://www.mrrse.com/

This release was published on openPR.